OCT 16, 2013 1:00 PM PDT

Molecular Diagnostics in Detection, Diagnosis, and Prognosis of Cancer

C.E. Credits: CE
Speakers
  • Assistant Professor, Biomedical Diagnostic & Therapeutic Sciences, , Oakland University
    Biography
      Kristin Landis-Piwowar is an Assistant Professor of Biomedical Diagnostic and Therapeutic Sciences at Oakland University in Rochester, MI. She earned a bachelors degree from Ferris State University in Medical Technology, a Masters degree in Clinical Laboratory Science from Michigan State University and a PhD in Cancer Biology from Wayne State Universitys School of Medicine in the laboratory of Q. Ping Dou. Landis-Piwowar was awarded a post-doctoral fellowship at the University of Michigan, Department of Pathology, where she conducted research to understand CD30 signaling to NFkB in anaplastic large cell lymphoma. Landis-Piwowar joined the faculty at Oakland University in Rochester, MI where she currently holds rank as an Assistant Professor of Biomedical Diagnostic and Therapeutic Sciences. Landis-Piwowar has published more than 25 peer-reviewed journal articles on cancer therapeutics, prevention, and mechanisms of disease and has authored numerous book chapters. Her research interests are centered on the physiologic effects of gold-peptidomimetics in cancer cells, and deciphering a familial relationship among chronic lymphocytic leukemia and hairy cell leukemia.

    Abstract:

    Cancer cells have historically been classified by microscopic analysis of blood smears and tissue sections. Current technologies use molecular techniques to categorize and classify tumor cells by the identification of chromosomal aberrations, and the increased or decreased expression of genes and gene products. Both genomics (the study of genes) and proteomics (the study of proteins) are therefore essential components of molecular diagnostics, which determines how genes and proteins interact in a cell. The molecular signature or profile of a cancer cell can be determined by the presence or absence of gene activity in cancer and pre-cancerous cells by real time PCR, fluorescence in situ hybridization, microarrays, etc. This profile allows for enhanced detection, earlier and more accurate diagnosis and prognosis, and can aid the physician in determining if cancer cells persist after treatment, all of which, are factors that contribute to the highest quality in patient care. Objectives: 1. Contrast oncogenes with tumor-suppressor genes and list three of each 2. Explain loss of heterozygosity and a common mechanism of its detection 3. Describe FISH and its application in one type of cancer


    Show Resources
    You May Also Like
    SEP 05, 2019 4:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 4:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    AUG 27, 2019 9:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 9:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    FEB 26, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    NOV 21, 2019 9:00 AM PST
    C.E. CREDITS
    NOV 21, 2019 9:00 AM PST
    DATE: November 21, 2019TIME: 9:00am PST, 12:00pm EST Multiple Myeloma is a disease of terminally differentiated plasma cells with the massive production of monoclonal immunoglobu...
    Loading Comments...
    Show Resources